Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836576 · ClinicalTrials.gov registry record · Phase 1
Benazepril HCl 40 mg Tablets, Fasting
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00836576: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00836576 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00836576, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals Corporation) in a test population of 40 adults under fasting conditions.
Interventions
- DRUG Benazepril HCl 40 mg Tablets
- DRUG Lotensin® 40 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-02 |
| Est. Completion | 2001-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836576
The ClinicalTrials.gov registry entry for NCT00836576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benazepril HCl 40 mg Tablets is the first listed.
NCT00836576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836576 about?
NCT00836576 is a clinical study titled "Benazepril HCl 40 mg Tablets, Fasting". The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals C...
What is the current status of trial NCT00836576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2001-02. Estimated completion is 2001-03.
What interventions are being tested in trial NCT00836576?
The interventions under investigation include: Benazepril HCl 40 mg Tablets (DRUG), Lotensin® 40 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00836576?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.